Interestingly, sacubitril/valsartan, an angiotensin receptor–neprilysin inhibitor (ARNI), may have beneficial effects on cardiac and renal outcomes in patients with heart failure with reduced ejection fraction (HFrEF), particularly by slowing the rate of decrease in the estimated glomerular filtration rate (eGFR) compared to a single angiotensin–converting enzyme inhibitor (ACE-I) (enalapril) [3]. This evidence concerns the gene MME and heart failure.